Cargando…

Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients

BACKGROUND: Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB). Serum Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serological marker for fibrosis. The role of M2BPGi in prediction of HCC is unknown. AIM: To examine th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mak, Lung-Yi, To, Wai-Pan, Wong, Danny Ka-Ho, Fung, James, Liu, Fen, Seto, Wai-Kay, Lai, Ching-Lung, Yuen, Man-Fung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429346/
https://www.ncbi.nlm.nih.gov/pubmed/30918432
http://dx.doi.org/10.3748/wjg.v25.i11.1398
_version_ 1783405574342311936
author Mak, Lung-Yi
To, Wai-Pan
Wong, Danny Ka-Ho
Fung, James
Liu, Fen
Seto, Wai-Kay
Lai, Ching-Lung
Yuen, Man-Fung
author_facet Mak, Lung-Yi
To, Wai-Pan
Wong, Danny Ka-Ho
Fung, James
Liu, Fen
Seto, Wai-Kay
Lai, Ching-Lung
Yuen, Man-Fung
author_sort Mak, Lung-Yi
collection PubMed
description BACKGROUND: Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB). Serum Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serological marker for fibrosis. The role of M2BPGi in prediction of HCC is unknown. AIM: To examine the role of serum M2BPGi in predicting HCC development in hepatitis B e antigen (HBeAg)-negative patients. METHODS: Treatment-naive CHB patients with documented spontaneous HBeAg seroconversion were recruited. Serum M2BPGi was measured at baseline (within 3 years from HBeAg seroconversion), at 5 years and 10 years after HBeAg seroconversion and expressed as cut-off index (COI). Multivariate cox regression was performed to identify predictors for HCC development. ROC analysis was used to determine the cut-off value of M2BPGi. RESULTS: Among 207 patients (57% male, median age at HBeAg seroconversion 40 years old) with median follow-up of 13.1 (11.8-15.5) years, the cumulative incidence of HCC at 15 years was 7%. Median M2BPGi levels were significantly higher in patients with HCC compared to those without HCC (baseline: 1.39 COI vs 0.38 COI, P < 0.001; 5-year: 1.45 COI vs 0.47 COI, P < 0.001; 10-year: 1.20 COI vs 0.55 COI, P = 0.001). Multivariate analysis revealed age at HBeAg seroconversion [odds ratio (OR) = 1.196, 95% confidence interval (CI): 1.034-1.382, P = 0.016] and baseline M2BPGi (OR = 4.666, 95%CI: 1.296-16.802, P = 0.018) were significant factors predictive of HCC. Using a cut-off value of 0.68 COI, baseline M2BPGi yielded AUROC of 0.883 with 91.7% sensitivity and 80.8% specificity. CONCLUSION: High serum M2BPGi within 3 years after HBeAg seroconversion was a strong predictor for subsequent HCC development in treatment-naive HBeAg-negative CHB patients.
format Online
Article
Text
id pubmed-6429346
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-64293462019-03-27 Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients Mak, Lung-Yi To, Wai-Pan Wong, Danny Ka-Ho Fung, James Liu, Fen Seto, Wai-Kay Lai, Ching-Lung Yuen, Man-Fung World J Gastroenterol Retrospective Study BACKGROUND: Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB). Serum Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serological marker for fibrosis. The role of M2BPGi in prediction of HCC is unknown. AIM: To examine the role of serum M2BPGi in predicting HCC development in hepatitis B e antigen (HBeAg)-negative patients. METHODS: Treatment-naive CHB patients with documented spontaneous HBeAg seroconversion were recruited. Serum M2BPGi was measured at baseline (within 3 years from HBeAg seroconversion), at 5 years and 10 years after HBeAg seroconversion and expressed as cut-off index (COI). Multivariate cox regression was performed to identify predictors for HCC development. ROC analysis was used to determine the cut-off value of M2BPGi. RESULTS: Among 207 patients (57% male, median age at HBeAg seroconversion 40 years old) with median follow-up of 13.1 (11.8-15.5) years, the cumulative incidence of HCC at 15 years was 7%. Median M2BPGi levels were significantly higher in patients with HCC compared to those without HCC (baseline: 1.39 COI vs 0.38 COI, P < 0.001; 5-year: 1.45 COI vs 0.47 COI, P < 0.001; 10-year: 1.20 COI vs 0.55 COI, P = 0.001). Multivariate analysis revealed age at HBeAg seroconversion [odds ratio (OR) = 1.196, 95% confidence interval (CI): 1.034-1.382, P = 0.016] and baseline M2BPGi (OR = 4.666, 95%CI: 1.296-16.802, P = 0.018) were significant factors predictive of HCC. Using a cut-off value of 0.68 COI, baseline M2BPGi yielded AUROC of 0.883 with 91.7% sensitivity and 80.8% specificity. CONCLUSION: High serum M2BPGi within 3 years after HBeAg seroconversion was a strong predictor for subsequent HCC development in treatment-naive HBeAg-negative CHB patients. Baishideng Publishing Group Inc 2019-03-21 2019-03-21 /pmc/articles/PMC6429346/ /pubmed/30918432 http://dx.doi.org/10.3748/wjg.v25.i11.1398 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Mak, Lung-Yi
To, Wai-Pan
Wong, Danny Ka-Ho
Fung, James
Liu, Fen
Seto, Wai-Kay
Lai, Ching-Lung
Yuen, Man-Fung
Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
title Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
title_full Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
title_fullStr Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
title_full_unstemmed Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
title_short Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients
title_sort serum mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in e-negative chronic hepatitis b patients
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429346/
https://www.ncbi.nlm.nih.gov/pubmed/30918432
http://dx.doi.org/10.3748/wjg.v25.i11.1398
work_keys_str_mv AT maklungyi serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients
AT towaipan serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients
AT wongdannykaho serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients
AT fungjames serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients
AT liufen serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients
AT setowaikay serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients
AT laichinglung serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients
AT yuenmanfung serummac2bindingproteinglycosylationisomerlevelpredictshepatocellularcarcinomadevelopmentinenegativechronichepatitisbpatients